Publicaciones en las que colabora con MARÍA DOLORES CABALLERO BARRIGÓN (13)

2016

  1. GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: Results of a multicenter study

    Bone Marrow Transplantation

2015

  1. Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant

    British Journal of Haematology, Vol. 169, Núm. 5, pp. 719-725

  2. Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome

    Leukemia Research, Vol. 39, Núm. 8, pp. 828-834

2014

  1. Late differentiation syndrome in acute promyelocytic leukemia: A challenging diagnosis

    Hematology Reports, Vol. 6, Núm. 4, pp. 75-77

  2. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

    Bone Marrow Transplantation, Vol. 49, Núm. 5, pp. 684-690

  3. Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585

2012

  1. Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation

    Transfusion, Vol. 52, Núm. 5, pp. 1086-1091

2011

  1. Effect of vitamin D treatment in chronic GVHD

    Bone Marrow Transplantation

2010

  1. Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant

    American Journal of Hematology, Vol. 85, Núm. 4, pp. 290-293

2009

  1. Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 15, Núm. 10, pp. 1331-1336

2008

  1. Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health Scale Plus the Type of Onset Can Predict Survival Rates and the Duration of Immunosuppressive Therapy

    Biology of Blood and Marrow Transplantation, Vol. 14, Núm. 10, pp. 1163-1171

2006

  1. Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Acute Graft-versus-Host Disease (GVHD)

    Biology of Blood and Marrow Transplantation, Vol. 12, Núm. 9, pp. 936-941

2005

  1. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena

    American Journal of Hematology, Vol. 78, Núm. 4, pp. 302-305